-transparent.png){kind=logo}
The purpose of this report is to assess whether phenotyping by three monoclonal antibodies routinely used in paraffin sections (Ber-H2-Leu-M1-EMA) and shown to be the most useful for diagnosis may be a predictive factor for recurrences. Among 563 patients diagnosed as having Hodgkin's disease (24% of whom had recurrence), we selected 153 patients with and without recurrence, with matching clinical stage. For all of these cases, histologic material was tested by immunostainings with satisfactory control samples. No phenotype was specific for Hodgkin's disease, although the phenotype Ber-H2-Leu-M1-EMA was predominant. No phenotype was found to be a predictive factor for recurrences, and none was unchanged during the clinical course, except when recurrence occurred as non-Hodgkin's lymphoma.
I de Mascarel, and
M Trojani, and
H Eghbali, and
J M Coindre, and
F Bonichon
June 1986,
Archives of pathology & laboratory medicine,
I de Mascarel, and
M Trojani, and
H Eghbali, and
J M Coindre, and
F Bonichon
April 1986,
American journal of clinical pathology,
I de Mascarel, and
M Trojani, and
H Eghbali, and
J M Coindre, and
F Bonichon
November 1985,
American journal of clinical pathology,
I de Mascarel, and
M Trojani, and
H Eghbali, and
J M Coindre, and
F Bonichon
July 1992,
The American journal of pathology,
I de Mascarel, and
M Trojani, and
H Eghbali, and
J M Coindre, and
F Bonichon
January 1991,
Neoplasma,
I de Mascarel, and
M Trojani, and
H Eghbali, and
J M Coindre, and
F Bonichon
November 1985,
Archives of pathology & laboratory medicine,
I de Mascarel, and
M Trojani, and
H Eghbali, and
J M Coindre, and
F Bonichon
May 1989,
Cancer,
I de Mascarel, and
M Trojani, and
H Eghbali, and
J M Coindre, and
F Bonichon
February 1994,
American journal of clinical pathology,
I de Mascarel, and
M Trojani, and
H Eghbali, and
J M Coindre, and
F Bonichon
January 1987,
Medicina,
I de Mascarel, and
M Trojani, and
H Eghbali, and
J M Coindre, and
F Bonichon
May 1986,
Archives of pathology & laboratory medicine,
